Zachary Clayton


Zach joined the Integrative Physiology of Aging (IPA) Laboratory as a postdoctoral fellow in 2018 after receiving his PhD in Human Physiology at the University of Oregon. To support his Postdoctoral Fellowship, Zach was awarded a National Institutes of Health (NIH) F32 award to determine potential mechanisms underlying vascular dysfunction induced by the common chemotherapeutic agent, doxorubicin. In 2022, Zach received an NIH K99/R00 award and was promoted to Assistant Research Professor at the University of Colorado Boulder in the Department of Integrative Physiology. Zach’s current research is primarily focused on determining the role of cellular senescence in mediating vascular dysfunction in the settings of advanced age and following chemotherapy treatment. The broad goal of this work is to identify basic mechanisms (i.e., therapeutic targets) that can be “aimed” at to improve cardiovascular health in these patient populations. Zach was named as an Assistant Director of the IPA Laboratory in 2022.